512 related articles for article (PubMed ID: 20014980)
1. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
4. Iron therapy in chronic kidney disease: current controversies.
Kovesdy CP; Kalantar-Zadeh K
J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
[TBL] [Abstract][Full Text] [Related]
5. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
Tagboto S; Cropper L; Turner J; Pugh-Clarke K
J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
[TBL] [Abstract][Full Text] [Related]
7. [IV iron or oral iron in anaemic patient with CKD].
Frimat L; Thilly N; Boini S
Nephrol Ther; 2006 Nov; 2 Suppl 5():S347-9. PubMed ID: 17373282
[TBL] [Abstract][Full Text] [Related]
8. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
9. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
Rottembourg J; Rostoker G
Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
[TBL] [Abstract][Full Text] [Related]
10. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
11. Iron replacement and supplementation in patients with chronic kidney disease.
Wazny LD; Raymond CB
CANNT J; 2011; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
13. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
18. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
19. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
Qunibi WY; Martinez C; Smith M; Benjamin J; Mangione A; Roger SD
Nephrol Dial Transplant; 2011 May; 26(5):1599-607. PubMed ID: 20929915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
